QM · rank #2 · 2026-05-15
ARWR
NASDAQ · $10.24B
Why this pick · factor scores
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +451.28% |
| ROE TTM Return on equity, trailing 12 months. | +75.5% |
| Profit margin Net profit margin, trailing 12 months. | +18.5% |
| Market cap Size filter: > $500M required. | $10.24B |
| Anchor (recent) Close on 2026-04-15 | $70.95 |
| Anchor (far) Close on 2025-04-15 | $12.87 |
AI research card
Independent qualitative review before order placement.
Summary
Arrowhead Pharmaceuticals Inc. is a biotechnology company focused on developing RNA interference (RNAi) therapeutics to treat intractable diseases by silencing disease-causing genes.
Rationale
The strong momentum and high profitability (ROE and profit margin) suggest that the market is positively reacting to Arrowhead's recent advancements in its RNAi pipeline and commercialization efforts, particularly with its FDA-approved drug REDEMPLO and other promising clinical candidates.
Material risks
- 1Clinical trial failures or delays for its numerous pipeline candidates could significantly impact future revenue and stock performance.
- 2Intense competition within the biotechnology and RNAi therapeutics space, including ongoing patent litigation, could limit market share and profitability.
Verdict reasoning
While strong signals exist, the inherent risks of a clinical-stage biotech with recent earnings reporting and competitive pressures warrant careful consideration.